摘要
多准则决策分析(MCDA)是一种能够帮助决策者系统地考虑多种准则的综合分析方法,已用于化学药、中成药等药品临床综合评价。该文对MCDA的理论基础及其在药品临床综合评价中的应用进行概述,并提出建议。MCDA过程包括问题识别与构建;模型构建;使用模型获取信息,经挑战性思考形成决策。其中,模型构建包括价值测量法、级别优先法和目标规划法三类,价值测量法是医药卫生领域最常用的方法。MCDA具体实施步骤由明确决策问题、选择和建立评估准则、测量绩效、对备选方案打分、对准则赋权、计算总得分、处理不确定性、报告撰写及结果审查组成。中成药作为中医药的重要组成部分,亟需开展临床综合评价,以促进其科学化、同质化和规范化,应用MCDA开展中成药临床综合评价意义重大。在应用MCDA开展中成药临床综合评价的过程中应以需求为导向、多方统筹协同,同时参考国际有益经验和成功实践,建立中成药临床综合评价的技术指南、规范与评价工具,最终为满足中成药供应和政策制定提供技术支撑。
Multi-criteria decision analysis(MCDA),a comprehensive analysis method that can help decision-makers consider multiple criteria systematically,has been used for clinical comprehensive evaluation of drugs,such as chemicals and Chinese patent medicines.The present study summarized the theoretical basis of MCDA and its application in the clinical comprehensive evaluation of drugs and put forward suggestions.MCDA includes problem identification,structuring problem,model building,and using the model to inform and challenge thinking to develop an action plan.The modeling methods include value measurement models,outranking models,and reference-level models.The value measurement model is the most commonly used method in healthcare.The implementation steps of MCDA consist of defining the decision problem,selecting and structuring criteria,measuring performance,scoring alternatives,weighting criteria,calculating aggregate scores,dealing with uncertainty,and reporting and examination of findings.It is urgent to carry out the clinical comprehensive evaluation of Chinese patent medicine,the important part of traditional Chinese medicine(TCM),to promote its scientization,homogenization,and standardization.It is of great significance to carry out the clinical comprehensive evaluation of Chinese patent medicine with MCDA,which should be demand-oriented,coordinated by many parties,and learn from international experience and successful practice to establish the corresponding technical guidelines,specifications,and evaluation tools,so as to provide technical support for Chinese patent medicine supply and policy formulation.
作者
戴泽琦
徐思敏
吴雪
李苗苗
胡晶
廖星
DAI Ze-qi;XU Si-min;WU Xue;LI Miao-miao;HU Jing;LIAO Xing(Center for Evidence-based Chinese Medicine,Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Institute of Basic Theory for Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing Institute of Traditional Chinese Medicine,Beijing 100700,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2022年第12期3155-3160,共6页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(82174239)
中国中医科学院科技创新工程项目(CI2021A00701-3)
中国中医科学院基本科研业务费优秀青年科技人才(创新类)培养专项(ZZ13-YQ-075)
中国中医科学院第十四批基本科研业务课题(Z0724)
中国中医药循证医学中心“业务研究室主任”专项(2020YJSZX-2)。
关键词
多准则决策分析
临床综合评价
中成药
卫生技术评估
循证决策
multi-criteria decision analysis(MCDA)
clinical comprehensive evaluation
Chinese patent medicine
health technology assessment(HTA)
evidence-based decision-making
